Posted in Innovation treatments

CAR T-Cell Therapy Lies Ahead for the Future of Cancer Treatment

Posted by Manuela Boyle on 18 December 2021
CAR T-Cell Therapy Lies Ahead for the Future of Cancer Treatment
Chimeric antigen receptor (CAR) T-cell therapy has the potential to replace chemoimmunotherapy for second-line treatment of patients with large B-cell lymphoma (LBCL) that have relapsed or are refractory to first-line therapy, results of the phase 3 ZUMA-7 and TRANSFORM trials suggest. In the ZUMA-7 trial, at a median follow-up of 24.9 months, patients randomly assigned to receive CAR T-cell therapy with axicabtagene ciloleucel, or axi-cell (Yescarta) had a median event-free survival (EFS) o...
Posted in:NewsEvidence Based ResearchCancerInnovation treatments  

Associations

  • The Institute for Functional Medicine
  • Society for Integrative Oncology
  • American Society of Clinical Oncology
  • Australian Traditional-Medicine Society
  • Naturopaths and Herbalists Association of Australia